★ Metabolic

Tirzepatide

Metabolic · 5mg × 10 vials

GLP-1 + GIP dual agonist. The once-weekly reference compound for weight and glycemic endpoints.

✓ 98%+ Purity ✓ Lab Tested ✓ COA on Request ✓ Discreet Shipping ✓ Direct Support

📋 Certificate of Analysis Request the third-party COA via Telegram ↗

$95from · 10-vial kit

Shipping: $40 US · $60 international (10-vial kits only) · single vials $20, US only · free over $1,000

5mg × 10 vials$95

10mg × 10 vials$115 / $39 single

15mg × 10 vials$135

20mg × 10 vials$155 / $59 single

30mg × 10 vials$190 / $69 single

40mg × 10 vials$240

45mg × 10 vials$260

50mg × 10 vials$295

60mg × 10 vials$340 / $109 single

100mg × 10 vials$515

Order / Consult on Telegram →

Overview

What Is Tirzepatide?

Tirzepatide is a 39-amino-acid long-acting peptide that activates two incretin receptors simultaneously: the GLP-1 receptor (appetite suppression, delayed gastric emptying, glucose-dependent insulin secretion) and the GIP receptor (glucose-dependent insulinotropic polypeptide, which amplifies insulin response, blunts glucagon, and appears to soften the nausea profile relative to pure GLP-1 agonists). The molecule is built on a GIP backbone with a C20 fatty di-acid moiety that binds albumin and extends the half-life to about five days.

The dual-receptor mechanism produces greater appetite suppression and larger weight reductions than semaglutide in head-to-head trials: SURMOUNT-5 (2025) reported 20.2% body-weight reduction with tirzepatide versus 13.7% with semaglutide over 72 weeks. The GIP component is also credited with improved tolerability at matched levels of appetite suppression. Tirzepatide is approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnoea).

Published Safety Data

What the published studies measured.

What the studies show

Measured in clinical trials

Nausea: 24-33% at 15 mg (SURMOUNT-1) - mild to moderate, peaks during 20-week dose-escalation window, mostly resolves within 4-8 weeks of holding at a stable dose
Diarrhea: 17-23% at 15 mg - mild to moderate
Vomiting: 6-13% at 15 mg - mild to moderate, mostly at titration steps
Constipation: 11-17% - generally mild
Abdominal pain / bloating: 10-15%
Gallbladder events (cholelithiasis, cholecystitis): 1-2.5%, RR 1.97 vs placebo, scales with rate of weight loss not tirz directly
Pancreatitis: <0.2% (class signal, not tirz-specific)
Discontinuation due to AEs: 4.3-7.1% across SURMOUNT-1 to SURMOUNT-4, vs 2.6% placebo. Pooled rate 1-10.5% by trial arm.

The Research

Peer-reviewed studies and clinical guidelines - tap any to read the source.

PubMedJastreboff et al, SURMOUNT-1, NEJM 2022

pivotal Phase 3, 2,539 pts, 20.9% body weight loss at 15 mg over 72 wk

Read study ↗PubMedSURMOUNT-1 long-term 176-week extension, NEJM 2024

19.7% sustained loss at 15 mg over 176 wk

Read study ↗PubMedFrias et al, SURPASS-2, NEJM 2021

head-to-head vs semaglutide in T2D, 2.30% A1C reduction at 15 mg vs 1.86% sema

Read study ↗PubMedSURMOUNT-4 maintenance trial, JAMA 2024 (PMC10714284)

](https://pmc.ncbi.nlm.nih.gov/articles/PMC10714284/) - 14% weight regain in placebo arm after withdrawal, 25.3% total loss with continued tirz

Read study ↗PubMedRubino et al, GI tolerability pooled analysis SURMOUNT-1 to -4, DOM 2025

pooled AE rates, discontinuation 1-10.5% by arm